FTSE MIB
28.243,26 +80,23 (+0,28%) Dow Jones
33.513,89 -152,45 (-0,45%) Nasdaq
13.233,27 +32,00 (+0,24%) Nikkei 225
31.857,62 -14,90 (-0,05%) Petrolio
90,74 -0,97 (-1,06%) Bitcoin EUR
25.470,01 -80,53 (-0,32%)
Editas Medicine, Inc. (0IFK.L)
| Chiusura precedente | 7,00 |
| Aperto | 7,86 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 7,51 - 8,55 |
| Intervallo di 52 settimane | 6,49 - 14,12 |
| Volume | |
| Media Volume | 2.586 |
| Capitalizzazione | 3,817M |
| Beta (5 anni mensile) | 1,79 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,73 |
| Prossima data utili | 31 ott 2023 - 06 nov 2023 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireEditas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and Strategy Officer, Caren Deardorf. In connection with Ms. Deardorf’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Ms. Deardorf as an inducement material to Ms. Deardorf entering into employment with Editas Medicine in accordan
GlobeNewswireEditas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
Caren Deardorf Editas Medicine, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine’s commercial organization, strategy, and execution to support a
- GlobeNewswire
Editas Medicine Announces Upcoming Investor Events
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences: 2023 Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Thursday, September 7Time: 3:00 p.m. ETLocation: Boston, MA Morgan Stanley 21st Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Monday, September 11Time: 10:00 a.m. ETLocation: New York, NY Can
